Somerset Pharma

Executive Summary

Somerset Pharma, founded in 2018 and headquartered in Tampa, Florida, is a private generic pharmaceutical company focused on manufacturing and supplying affordable, bioequivalent generic medicines across diverse therapeutic segments, including injectables, ophthalmics, and oral solids. The company aims to enhance healthcare accessibility and sustainability by providing high-quality, low-cost alternatives to brand-name drugs. Despite being a relatively new entrant, Somerset Pharma has established a broad portfolio and positions itself as a reliable partner for healthcare providers and patients. The generic drug market continues to grow due to patent expirations and cost-saving initiatives, offering a favorable tailwind. However, as a privately held firm with limited public disclosures, its growth trajectory and competitive standing are not easily benchmarked. Nonetheless, its focus on quality and affordability aligns with industry trends, and its presence in multiple dosage forms suggests potential for steady revenue contributions. The company's ability to navigate regulatory hurdles and secure timely FDA approvals will be key to its success.

Upcoming Catalysts (preview)

• Q3 2026FDA Approval of a New Abbreviated New Drug Application (ANDA)70% success
• TBDExpansion into New Therapeutic Categories via Licensing or Acquisition40% success
• Q4 2026Launch of a High-Volume Generic Product60% success